BSH 2024 | The real-world safety and efficacy of CPX-351 in patients with AML
Priyanka Mehta, MBBS, MD, FRCP, FRCPath, University Hospitals Bristol NHS Foundation Trust, Bristol, UK, briefly discusses the real-world safety and efficacy data collected when using CPX-351 to treat patients with acute myeloid leukemia (AML). These data confirmed the efficacy of the drug in younger patients and answered questions about measurable residual disease (MRD) responses and transplant outcomes. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
The real-world data that we collected on patients that were treated with CPX-351 (Vyxeos®) was very exciting because it answered some of the gaps in the data that was generated when the pivotal study was published in that we have now got data which shows that CPX-351 works just as well and probably even better in younger patients. And the response rates that we are seeing in the real world are actually even better than what was published in the study...
The real-world data that we collected on patients that were treated with CPX-351 (Vyxeos®) was very exciting because it answered some of the gaps in the data that was generated when the pivotal study was published in that we have now got data which shows that CPX-351 works just as well and probably even better in younger patients. And the response rates that we are seeing in the real world are actually even better than what was published in the study. It also answers some of the questions about MRD responses in AML patients, which is all very encouraging, and particularly the transplant outcomes post CPX-351, which remains one of the most important findings in establishing that the best long term outcome for these patients with high-risk AML is using CPX-351 consolidated with an allogeneic transplant where possible.
Read more...
Disclosures
Speaker/Advisory fees: Jazz, Pfizer, Menarini, Abbvie, Astellas.
